Showing results (2301-2310 of 2,413) with videos related to

Sort By:
Pageof 242
The Lancet. Oncology|September 4, 2025
Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of CancerIan F Tannock, Madeline Lee Pe, Christopher M Booth, et al.
Blood Advances|January 4, 2018
Novel GM-CSF signals via IFN-γR/IRF-1 and AKT/mTOR license monocytes for suppressor functionEliana Ribechini, James A Hutchinson, Sabine Hergovits, et al.
Acta Oncologica (Stockholm, Sweden)|May 1, 2015
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104Stephan Kruger, Stefan Boeck, Volker Heinemann, et al.
Nature Communications|February 17, 2025
BMP signaling promotes zebrafish heart regeneration via alleviation of replication stressMohankrishna Dalvoy Vasudevarao, Denise Posadas Pena, Michaela Ihle, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|June 25, 2008
A cell-based approach to the minimization of immunosuppression in renal transplantationJames A Hutchinson, Beate G Brem-Exner, Paloma Riquelme, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2018
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO studyArndt Vogel, Stefan Kasper, Michael Bitzer, et al.
Annals of Surgery|May 11, 2016
Patient Blood Management is Associated With a Substantial Reduction of Red Blood Cell Utilization and Safe for Patient's Outcome: A Prospective, Multicenter Cohort Study With a Noninferiority DesignPatrick Meybohm, Eva Herrmann, Andrea U Steinbicker, et al.
Journal of Cancer Policy|May 13, 2022
The European Code of Cancer PracticeMark Lawler, Kathy Oliver, Stefan Gijssels, et al.
Kidney International|October 28, 2022
A Phase I/IIa study of autologous tolerogenic dendritic cells immunotherapy in kidney transplant recipientsAurélie Moreau, Delphine Kervella, Laurence Bouchet-Delbos, et al.
Gut|July 10, 2012
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)Volker Heinemann, Ursula Vehling-Kaiser, Dirk Waldschmidt, et al.
Pageof 242